drugset / Trial / NCT02106507
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Phase 1
Completed
9 enrolled
Memorial Sloan Kettering Cancer Center
Aragon Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of the combination of apalutamide plus everolimus at different dose levels.
Timeline
- Start
- 2014-04
- Primary completion
- 2021-06-28
- Completion
- 2021-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apalutamide | Small molecule | 240 mg | Oral |
| Subject | Everolimus | Small molecule | 5 mg | — |
| Subject | Everolimus | Small molecule | 10 mg | — |